Virus like Particle Vaccines
Virus like Particles (VLPs) are nanoscale structures that self-assemble and mimic the structure of native viruses without being infectious. Due to their stability, size, and multivalence, VLPs are excellently suited as a basis for vaccines. They provide a safer alternative to attenuated or inactivated vaccines. They are able to induce potent cellular and humoral immune responses and can be produced recombinantly in microbial expression systems without the risk of contamination with infectious viruses. Another possibility is to use them as a packaging tool for nucleic acids and drug substances, as they can transport agents.
The ARTES vaccine technology platform is based on enveloped virus-like particles (eVLPs) derived from the recombinant duck hepatitis B virus surface antigen (dS) or capsid-like virus-like particles (cVLPs) derived from the core hepatitis B antigen.
These vaccine platforms, in combination with our efficient and proven microbial expression platforms, are the optimal solution for the economical production of a safe and effective recombinant subunit vaccine. Our goal is to meet your requirements 100%.
Our vaccine platform technologies enable efficient expression, folding and presentation of the target antigen on the surface of chimeric VLPs. These nanostructures improve recognition and uptake by antigen-presenting cells, leading to a strong immune response against the respective target antigen in the target organism.
The ARTES technology platform has proven itself in various development projects for our customers.
Preclinical studies have demonstrated the safety, tolerability and high immunogenicity of adjuvant-free vaccine candidates for diseases such as swine flu, malaria, HIV and Lyme disease.
METAVAX® – enveloped virus like particles
designed for the development of novel, highly immunogenic nanoparticle subunit vaccines in human and animal health
Our platform METAVAX®, efficiently expresses, folds, and presents your target antigen on the surface of VLPs. It has been successfully utilized in various vaccine development projects for both human and animal targets.
Features of METAVAX®:
- well suited for human and veterinary vaccines
- presentation of large target antigens and conformational epitopes
- versatile expression of targets as e.g. N- or C-terminal fusion proteins
- rapid feasibility studies by generic processes and analytics
Hep-B Core – capsid virus like particles
development of vaccine candidates based on proprietary antigen presentation by Virus like Particles
We offer two different presentation forms for the development of capsid Virus like Particles (cVLPS): the traditional single chain HB Core and a novel Hep-B Core scaffold (SplitCore). This ensures optimal integration and presentation of structurally different antigens.
Features of Hep-B Core:
- self-assembling into protein-only capsid VLPs (no host lipids)
- with or without nucleic acid binding domain for modulation of the immunogenicity (adjuvant effect of nucleic acid)
- for presentation of epitopes and antigens up to 50 kDa
- supports drug delivery applications (encapsulation of actives)
- produced in yeast or in E. coli at high productivity rates
- platform for presentation of large proteins, structurally complex and dimeric proteins